Daiichi Sankyo / 第一三共

Daiichi Sankyo appears in vol.120.日本医疗体系的崩溃与重生：医院、药品、医保三角困局的一种解法 as one of the Japanese pharma companies used to show that Japan retained globally meaningful pharmaceutical capability after the crisis and reform period.

In the source, the company is less a standalone case than a marker for Japanese Drug Pricing Reform / 日本药品定价改革. Japan’s later approach tries to preserve affordable public insurance while leaving enough reward for quality, added value, and innovation that firms such as Daiichi Sankyo can still matter.

Connections

• Takeda Pharmaceutical / 武田制药 - paired Japanese pharma example in the source.
• Japanese Drug Pricing Reform / 日本药品定价改革 and Generic Drug Trust Rebuilding / 仿制药再信任 - policy context for Japanese pharma.
• Japanese Healthcare System / 日本医疗体系 and Japan - national healthcare and industry context.